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Abstract
Background: Cell surface sialylation is emerging as an important feature of cancer cell metastasis. Sialyltransferase
expression has been reported to be altered in tumours and may account for the formation of sialylated tumour antigens. We
have focused on the influence of alpha-2,3-sialyltransferase ST3Gal III in key steps of the pancreatic tumorigenic process.
Methodology/Principal Findings: ST3Gal III overexpressing pancreatic adenocarcinoma cell lines Capan-1 and MDAPanc-28
were generated. They showed an increase of the tumour associated antigen sialyl-Lewis
x. The transfectants’ E-selectin
binding capacity was proportional to cell surface sialyl-Lewis
x levels. Cellular migration positively correlated with ST3Gal III
and sialyl-Lewis
x levels. Moreover, intrasplenic injection of the ST3Gal III transfected cells into athymic nude mice showed a
decrease in survival and higher metastasis formation when compared to the mock cells.
Conclusion: In summary, the overexpression of ST3Gal III in these pancreatic adenocarcinoma cell lines underlines the role
of this enzyme and its product in key steps of tumour progression such as adhesion, migration and metastasis formation.
Citation: Pe ´rez-Garay M, Arteta B, Page `s L, de Llorens R, de Bolo `s C, et al. (2010) a2,3-Sialyltransferase ST3Gal III Modulates Pancreatic Cancer Cell Motility and
Adhesion In Vitro and Enhances Its Metastatic Potential In Vivo. PLoS ONE 5(9): e12524. doi:10.1371/journal.pone.0012524
Editor: Terence Lee, University of Hong Kong, Hong Kong
Received May 7, 2010; Accepted July 31, 2010; Published September 1, 2010
Copyright:  2010 Pe ´rez-Garay et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by La Marato de TV3 foundation (grant 050932, awarded to R.P.), Spanish Ministerio de Ciencia e Innovacion (grant BIO 2007-
61323, awarded to R.P.), the Government of Catalonia (grant 2005SGR00065, awarded to R.L.), the Comision Interministerial de Ciencia y Tecnologı ´-a (CICYT) of the
Spanish Government in Madrid (no. SAF2006-09341, awarded to F.V.V.) and the Basque Country Government (no. IT-487-07 awarded to F.V.V.). M.P.-G. thanks
Fundacio ´ La Marato ´ for a pre-doctoral fellowship and University of Girona for a short-term mobility fellowship. The funders have no role in study design, data
collection and analysis, decision to publish or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rosa.peracaula@udg.edu
Introduction
Cell surface sialylation is emerging as an important feature of
cancer cell metastasis. Sialic acids and their derivatives are
ubiquitous at terminal positions of glycoconjugates. Those acidic
sugars impart net negative charge and are in a position to
modulate a wide variety of events in cell-cell, cell-matrix and cell-
molecule interactions [1]. The transfer of the sialic acids from
cystidine-5-monophospho-N-acetylneuraminic acid (CMP-NeuAc)
to the terminal positions of carbohydrate groups of glycoprotein
and glycolipids is catalyzed by sialyltransferases [2].
Human sialyltransferases are a family of 20 different intracel-
lular, Golgi membrane-bound glycosyltransferases; grouped in
three subfamilies [3]. Alpha-2,6-sialyltransferases mediate the
transfer of sialic acid with an alpha 2,6-linkage to terminal Gal
(ST6Gal I-II) [4,5]or GalNAc residues (ST6Gal NAc I-VI). Alpha-
2,8-sialyltransferases mediate the transfer of sialic acid with an
alpha 2,8-linkage (ST8 Sia I-IV). Alpha-2,3-sialyltransferases
mediate the transfer of sialic acid with an alpha 2,3-linkage to
terminal Gal residues. ST3Gal I-II and IV catalyze the
transference to the Gal residue located on terminal Galb1-
3GalNAc structures; ST3Gal IV and VI transfer sialic acid (with
alpha 2,3-linkage) to the Gal residue located on terminal Galb1-
4GlcNAc structures; ST3Gal V acts on the Gal residue located on
terminal Galb1-4Glc-Cer structures and finally, ST3Gal III
catalyzes the transfer of sialic acid with an alpha 2,3-linkage to
terminal Gal residues located on either Galb1-3GlcNAc or Galb1-
4GlcNAc structures [6].
Changes in specific sialyltransferase expression have been
reported to be altered in several tumours and may account for
the formation of sialylated tumour antigens, such as sialyl-Lewis x,
sialyl- Lewis a, sialyl-T and sialyl- Tn. In the extrahepatic bile duct
carcinoma ST3Gal III levels correlated with tumour advance-
ment, differentiation and metastasis [7]. In breast cancer, the most
expressed sialyltransferase was ST3Gal III which positively
correlated to tumour size and the number of axilary nodes; and
moreover high ST3Gal III/ST6Gal I ratio was correlated with a
shorter overall survival and bad prognosis [8,9]. In addition,
ST6GalNAc V has recently been reported to mediate brain
metastasis of breast cancer cells [10]. In bladder cancer ST3Gal I
plays the major role in the sialylation of the T antigen and its
overexpression seems to be part of the initial oncogenic
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and ST3Gal III expression levels were significantly increased in
patients with lymph node metastasis when compared to those
without metastases [12,13] and ST3Gal III, ST3Gal IV and
ST6Gal I were increased in cervical intraepithelial neoplasia. In
human renal carcinoma a down-regulation of ST3Gal IV mRNA
may be one of the factors associated with its malignant progression
[14]. In colon cancer ST6Gal I and ST3Gal III increased their
expression in carcinoma specimens [15]. ST3Gal III was
prominently increased in cancer tissues compared with non-
malignant colorectal mucosa [16] and an elevation of ST6Gal I
activity was observed in malignant and transitional tissue [17]. In
gastric cancer, high levels of ST3Gal III a in the tumour tissue
correlated with secondary tumour recurrence [18].
Although alpha-2,3-sialyltransferase ST3Gal III expression corre-
lates with tumour malignancy in several carcinomas its mechanistic
role has not been fully evaluated. ST3Gal III is involved in the
biosynthesis of sialyl-Lewis antigens, which are overexpressed in
pancreatic adenocarcinoma (PDAC) [19,20,21,22,23,24], and corre-
late with its bad prognosis [25,26,27,28]. In the present work, our goal
has been to investigate the specific influence of the alpha-2,3-
sialyltransferase ST3Gal III in some of the key steps of the PDAC
progression such as adhesion, migration and metastasis. For that, we
have chosen two pancreatic adenocarcinoma cancer cell lines Capan-
1 and MDAPanc-28, with different ST3Gal III and sialyl-Lewis
antigen expression levels, and generated ST3Gal III overexpressing
clones. ST3Gal III increased expression was related to an increase
sialyl-Lewis
x surface level and conducted to an enhanced E-Selectin
binding capacity and cell migration. Furthermore, the intrasplenic
injection into athymic nude mice of the ST3Gal III overepressing cells
showed a decrease in mice survival and higher metastasis formation.
In summary, increased expression of ST3Gal III in those pancreatic
adenocarcinoma cell lines highlights the role of this enzyme and its
product in key steps of tumour progression such as adhesion,
migration and metastasis.
Results
Stable overexpression of ST3Gal III in Capan-1 and
MDAPanc-28 cells
To explore the mechanistic role of ST3Gal III in pancreatic
adenocarcinoma progression, the rat ST3Gal III gene, which
exhibits virtually identical acceptor specificity and enzymatic
activity as human ST3Gal III gene [29], was used. Thus, Capan-1
and MDAPanc-28 cells were transfected with the pcDNA 3.1
vector encoding rat ST3Gal III gene. Parental cells were
concomitantly transfected with the empty pcDNA3.1 vector.
Several stable cell clones were selected in the presence of
geneticine and ST3Gal III mRNA overexpression was analysed
by semi-quantitative PCR (data not shown). ST3Gal III mRNA
overexpressing clones, C31 and C32 (for the Capan-1 model) and
M33 and M34 (for the MDAPanc-28 model) were selected for
further studies. As controls, parental cell lines (Capan-1 and
MDAPanc-28) and mock transfected clones (CP for Capan-1 and
MP for MDA-Panc 28) were used. ST3Gal III mRNA expression
was quantified by quantitative PCR (qPCR) (Figure 1). Capan-1
parental cells had 3-fold higher (P,0.001) ST3Gal III expression
than MDAPanc-28 parental cells. Regarding the Capan-1 model,
ST3Gal III mRNA expression was 140-fold higher (P,0.001)i n
C31 clone and 100-fold higher (P,0.001) in C32 clone than in
Capan-1 and CP control cells. For the MDAPanc-28 model,
ST3Gal III mRNA expression was 7-fold higher (P,0.001)i n
M34 clone and 3.6-fold higher (P,0.001) in M33 clone than in
both control cells, MDAPanc-28 and MP. Evaluation of general
sialyltransferase activity was performed by Glycosylation Immu-
nosorbent assay (GISA) as previously described [24]. As expected,
a general sialyltransferase activity increase was detected in the
transfected cells when compared to their corresponding controls,
being about 3.2 fold higher in the Capan-1 ST3Gal III
overexpressing clones versus CP and Capan-1 and 1.3 fold higher
in the MDAPanc-28 ST3Gal III overexpressing clones versus MP
and MDAPanc-28.
ST3Gal III increased de novo expression of SLex by
enzymatic competition
Cell surface glycan expression pattern for both models was
studied by flow cytometry using specific monoclonal antibodies
against Lewis antigens and specific lectins (results shown in
Figure 2). The analysis of Type II Lewis antigens in the Capan-1
model (Figure 2A) revealed that Capan-1 and CP cells had high-
medium levels of the Le
x, SLe
x and H2 antigens and high levels of
the Le
y antigen. When compared to controls, C31 and C32 clones
displayed a large increase in SLe
x expression at the expense of
completely losing the expression of non-sialylated antigens (Le
x,
Figure 1. ST3Gal III expression normalized to b-actin of the pancreatic adenocarcionoma cells. MDAPanc-28 parental cells, MP:
MDAPanc-28 mock cells, M34 and M33: MDAPanc-28 cells transfected with the ST3Gal III gene. Capan-1: parental cells, CP: Capan-1 mock cells, C31
and C32: Capan-1 cells transfected with the ST3Gal III gene. Data represents the mean 6 SD of 3 separate experiments, each in six replicates (n=18). *
Significantly different (P,0.001).
doi:10.1371/journal.pone.0012524.g001
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y). Moreover, accompanying the increase in SLe
x,a
decrease in a2,6-sialic acid was observed, detected by Sambucus
nigra agglutinin (SNA). Maackia amurensis agglutinin (MAA) did not
show differences among clones, probably due to the fact that is
unable to bind to SLe
x structure (data not shown). Type I Lewis
antigens SLe
a,L e
a,L e
b and H1 were not detected in the Capan-1
model (data not shown). Thus, these results evidenced a multiple
enzymatic competition for Type II chains. The analysis of
MDAPanc-28 (Figure 2B) model showed that MDAPanc-28
and MP control cells had very low SLe
x expression and high a2,6-
Figure 2. Flow cytometry profiles of the cell surface glycan structures of the pancreatic adenocarcionoma cells. Figure 2A. Capan-1
(continous dot outline: ………), CP (spaced dot outline: . . . . . ), C31 (bold outline:_______), C32 (plain outline:______). Figure 2B. MDAPanc-28
(continous dot outline: ………), MP (spaced dot outline: .....) ,M 3 4(bold outline:_______), M33 (plain outline:______). Experiments were performed
for triplicate. Representative cytometry histograms are shown. Anti-Le
x MAb binds to Galb1,4[Fuca1,3]GlcNAc-; anti-SLe
x MAb binds to NeuAca2-
3Galb1,4[Fuca1,3]GlcNAc-; anti-H2 MAb binds to [Fuca1,2]Galb1,4GlcNAc-; anti-Le
y MAb binds to [Fuca1,2]Galb1,4[Fuca1,3]GlcNAc-; SNA lectin
(Sambucus nigra agglutinin) binds to NeuAca2–6Galb- structures.
doi:10.1371/journal.pone.0012524.g002
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M33 and M34 clones were compared to controls, an increase in
SLe
x with a simultaneous decrease in a2,6-sialic acid was also
detected. As above, MAA did not show differences between clones
likely because it does not recognize SLe
x (data not shown). Since
ST3Gal III transfected clones C31 and C32 behaved similarly in
the Capan-1 model as well as the M33 and M34 ST3Gal III
transfected clones in the MDAPanc-28 model, the following in vitro
and in vivo studies were performed only with the highest ST3Gal
III and SLe
x expressing clones: C31 for the Capan-1 model and
M34 for the MDAPanc-28 model.
ST3Gal III enhanced pancreatic adenocarcinoma cells
adhesion to rh-E-selectin
E-selectin is a cell adhesion molecule expressed on activated
endothelial cells that recognizes and binds to specific carbohydrate
determinants, such as SLe
x and SLe
a present on surface glycocon-
jugates [30]. Binding assays to rh-E-selectin were performed to
analyse whether the different pattern of the Lewis antigen expression
was able to induce changes in the adhesion (results shown in
Figure 3). Both models showed different adhesion patterns to rh-E-
selectin. MDAPanc-28 parental cells displayed lower adhesion to rh-
E-selectinthan Capan-1 parental cells, whichwas consistent with the
lower expression level of ST3Gal III and SLe
x of MDAPanc-28
compared to Capan-1 cells. In the Capan-1 model (Figure 3A)t h e
ST3Gal III overexpressing clone, C31, tripled the adhesion
(P,0.001) to rh-E-selectin when compared to corresponding
controls Capan-1 and CP. To confirm that SLe
x expression induced
by ST3Gal III caused the up-regulated E-selectin binding, cells were
previouslyincubated with the anti-SLe
x monoclonalantibody(MAb)
and the binding to E-selectin was inhibited. In the MDAPanc-28
model (Figure 3B), the ST3Gal III overexpressing clone, M34,
quadrupled (P,0.001) the adhesion to rh-E-selectinwhen compared
to the corresponding controls MDAPanc-28 and MP. When cells
werepreviouslyincubatedwiththeanti-SLe
xMAbthebindingtoE-
selectin was completely abrogated. These results demonstrated that,
in these models, ST3Gal III levels modulated the in vitro binding to
rh-E-selectin via SLe
x expression.
The effect of different cytokines on the adhesion of
pancreatic cancer cells to hepatic sinusoidal endothelial
(HSE) cells
Because ST3Gal III and SLe
x expression levels were directly
proportional to in vitro rh-E-selectin adhesion, the binding of
pancreatic cancer cells to primary cultured HSE cells was
evaluated. The Capan-1 model was selected for this experiment
due its higher adhesion to rh-E-selectin. First, we determined the
specific adhesion of Capan-1 parental cells to HSEC stimulated
with TNF-a, IL1-b or lipopolysaccharide (LPS) for 16 hours
before the assay (results shown in Figure 4A). Treatment with
TNF-a and IL1-b greatly increased the number of adherent cells,
and IL1-b resulted to be the best stimuli for our model. When
incubating with anti-E-selectin MAb, the increase in adhesion was
completely abrogated. Those data showed that HSE cell cytokine
pre-treatment, especially IL-1b, promoted their E-selectin expres-
sion, which caused an increase of Capan-1 adhesion.
ST3Gal III increased tumour cell adhesion to HSE cells
We next determined the adhesion of different ST3Gal III and
SLe
x levels expressing Capan-1 cells to IL-1b pre-treated or
control HSE cells (results shown in Figure 4B). Capan-1 and CP
control cells showed a basal adhesion to HSE cells, which
significantly increased in IL-1b pre-treated HSE cells and returned
to basal levels in anti-E-selectin MAb pre-incubated HSE cells.
C31 showed a basal adhesion to HSE cells (higher than Capan-1
and CP control cells), which significantly increased in IL-1b pre-
treated HSE cells and also returned to basal levels in anti-E-
selectin MAb preincubated HSE cells. Those data showed that E-
selectin played an important role mediating adhesion to HSE cells,
although a non-E-selectin dependent basal adhesion (higher for
C31 than for control cells) existed. Moreover, high ST3Gal III and
SLe
x expressing C31 cells had a higher adhesion to HSE cells than
medium ST3Gal III and SLe
x expressing control cells.
ST3Gal III expression increased cell migration
To investigate whether ST3Gal III overexpressing clones might
lead to the acquisition of a more migratory cell phenotype, we
evaluated cell migration on collagen Type-I using a transwell
migration assay (results shown in Figure 5). Both cell models
showed different migratory capabilities, with the Capan-1 model
being nine times more migratory than the MDAPanc-28 model.
Regarding the Capan-1 model (Figure 5A), the ST3 Gal III and
SLe
x overexpressing clone C31 exhibited double (P,0.001)
migration capabilities than control cells Capan-1 and CP. For
the MDAPanc-28 model (Figure 5B), the ST3Gal III and SLe
x
Figure 3. Binding assay to rh-E-selectin. Capan-1 variant cells
(Figure 3A) and MDAPanc-28 variant cells (Figure 3B), previously
incubated with PBS-1% BSA (light bars) or anti-SLe
x MAb (dark bars),
were added to 96-well microplates coated with rh E-selectin or PBS-1%
BSA (negative control). Adherent cells were estimated with a MTT-based
colorimetric assay. Results are expressed as the Specific binding to E-
selectin (O.D. 570 nm of cells bounded to E-selectin – O.D. 570 nm of
cells bonded to PBS-1% BSA) versus cells previously incubated or not
with anti-SLe
x MAb. Data represents the mean 6 SD of 3 separate
experiments, each in five replicates (n=15). * Significantly different
(P,0.001).
doi:10.1371/journal.pone.0012524.g003
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respect to the control cells MDAPanc-28 and MP. Results
demonstrated a positive correlation between ST3Gal III and SLe
x
levels and migratory capabilities.
ST3Gal III overexpression increases tumourigenesis and
decreases survival in athymic nude mice
Since the in vitro results described above suggested an important
role for the ST3Gal III gene in tumour progression, in vivo assays
were performed to study whether ST3Gal III could be important
in tumour metastasis. First, the formation of metastasis and
survival of athymic nude mice after intrasplenic injection with
different amounts of the Capan-1 and MDAPanc-28 parental cells
were assayed. In our hands, when 1.5610
6,3 610
6 and 5610
6
Capan-1 cells were injected, the nude mice died of emboli
formation, probably due to the Capan-1 size and aggregation
capacity. The injection of 1610
6 Capan-1 cells did not form
emboli and generated spleen tumours, although without metastatic
focuses. Since MDAPanc-28 cells are 4–5 times smaller than
Capan-1 cells, 7610
6 MDAPanc-28 cells were injected intrasplen-
ically into nude mice, which generated small macroscopic
metastatic focuses in 2/3 of the mice, 20–22 weeks later.
Therefore, MP and M34 cells were chosen to study the influence
of ST3Gal III overexpression in metastasis formation and nude
mice survival. Exponentially growing 7610
6 viable MP and M34
cells, which share the same morphological characteristics, were
injected in the spleen of athymic nude mice (n=8/group) and
survival analysis was performed using the Kaplan-Meier method
(Figure 6). Mice injected with ST3Gal III overexpressing cells
(M34) showed a large decrease in survival (P=0.019) when
compared with mice injected with control MP cells. Most of the
M34 injected mice (5/8) died after 103–110 days post-injection,
Figure 4. E-selectin induction on Primary Cultured Hepatic
Sinusoidal endothelium (HSE) cells (Figure 4A). HSE cells were
incubated with ,Sel. = anti-murine CD62 E (E-selectin) MAb or
,IgG. = isotype-matched control antibody. Parental Capan-1 cells
were labelled with calcein and added to HSE control cells, TNF-a
stimulated HSE cells, LPS stimulated HSE cells or IL-1b stimulated HSE
cells. Results are expressed as the % Specific adhesion to HSE cells [78].
Data represents the mean 6 SD of 3 separate experiments, each in
three replicates (n=9). * Significantly different (P,0.001)w h e n
comparing anti-E-selectin incubated HSEC to control cells. # Signifi-
cantly different (P,0.001) when comparing treatments. Tumour cell
adhesion assay to Primary Cultured HSE cells (Figure 4B).
Capan-1 variant cells were labelled with Calcein and added to IL-1b
stimulated HSE cells or (2) not stimulated HSE control cells. ,Sel. =
anti-murine CD62 E (E-selectin) MAb was added to IL-1b HSE cells or -
HSE cells before tumour cell addition. * Significantly different (P,0.001)
when comparing Capan-1, CP, and C31 cells. # Significantly different
(P,0.001) when comparing each clone (Capan-1, CP and C31) adhesion
for the different HSE cell treatments.
doi:10.1371/journal.pone.0012524.g004
Figure 5. Cell migration assay. Capan-1 variant cells (Capan-1,CP
and C31) (Figure 5A) and MDAPanc-28 variant cells (MDAPanc-28, MP
and M34) (Figure 5B) were seeded onto 8 mm-pores-Type I-Collagen
coated inserts, placed on top of wells containing DMEM-1% FBS and
incubated at 37uC (6 h for Capan-1 model and 18 h for MDAPanc-28
model). Non-migrated cells were eliminated and migrated cells fixed,
stained and counted. Results are expressed as migrated cells per well.
Data represents the mean 6 SD of the values obtained in 3 separate
experiments, (n=9). * Significantly different (P,0.001).
doi:10.1371/journal.pone.0012524.g005
ST3Gal III & Pancreatic Cancer
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days). All M34 injected mice were necropsied and the analysis
showed spleen tumours in 62.5% of them (5/8) and several
macroscopic metastatic focuses to the bowel, diaphragm, kidney,
ganglia or suprarenal glands in 75% of the mice (6/8). All MP
injected mice were necropsied (days 103, 138, 161 and 190 post-
injection) and none of them (8/8) showed evidence of either spleen
tumours or macroscopic metastasis. Thus, the overexpression of
ST3Gal III in MDAPanc-28 cells, which lead to a higher
expression of SLe
x and a higher adhesion and migration, could
be directly correlated with a decrease in survival when injected in
nude mice. Furthermore, it endowed cells with a greater tumour
formation capability and metastatic potential when intrasplenically
injected.
Discussion
Our earlier studies showed that alpha-2,3-sialyltransferase
activity correlated to sialyl-Lewis antigen expression on pancreatic
cancer cell surfaces [24]. We therein extended our investigations to
specifically study the mechanistic role of ST3Gal III in the
acquisition of adhesive, migratory and metastatic capabilities in
pancreatic adenocarcinoma cancer cell lines. We have found that:
1) ST3Gal III mRNA expression levels correlated with SLe
x
surface expression; 2) ST3Gal III induced sialylation increased
pancreatic cancer adhesion to rh-E-Selectin and IL1-b pre-
stimulated HSE cells, via SLe
x-E-selectin interaction; 3) a positive
correlation between migration and ST3Gal III and SLe
x
expression; and 4) the intrasplenic injection of ST3Gal III
overexpressing cell lines in athymic nude mice induced an increase
in tumourigenesis and a decrease in survival.
ST3Gal III overexpressing clones (C31, C32, M33 and M34)
displayed an increase in SLe
x expression when compared to the
corresponding controls (untransfected cells, Capan-1 and MDA-
Panc-28, and cells transfected with the empty vector, CP and MP).
Although Type I substrate is considered ST3Gal III preferred
acceptor, Type II substrate is also a good acceptor. The enzymatic
studies carried out in order to characterize ST3Gal III activity
showed that Type I and Type II acceptor substrates led to quite
similar Vmax values, while Km values were much higher for type II.
As a consequence, incorporation rates were approximately twice
for Type I than for Type II structures [31]. Similar results were
obtained in later works on studying natural [32,33] or synthetic
acceptors specificities [34,35,36,37,38]. Taking into account that
the cell lines used in this study do not express type I Lewis antigens
and that ST3Gal III can act on both type I and II substrates, the
overexpression of ST3Gal III acted on type II precursors leading
to an increased expression of SLe
x. Recently, and in agreement
with our results, it has been described that overexpression of
ST3Gal III in gastrointestinal carcinoma cells also resulted in SLe
x
determinant increase [39]. Moreover, these authors described that
the mRNA levels of ST3Gal III correlated with increased SLe
x
expression levels in confluent cells, but not with the mRNA levels
of ST3Gal IV and ST3Gal VI, which are the enzymes that have
been reported to act preferentially on Type II chains. Taken
together, these data reinforce the role of ST3Gal III in the
biosynthesis of SLe
x in these carcinoma cells. Together with SLe
x
increase, a decrease in a2,6-sialic acid was observed in both
models. In addition, C31 and C32 showed a complete loss of non-
sialylated Type II Lewis antigens (Le
x, H2 and Le
y). These results
are likely explained by multiple enzymatic competition for Type II
chains. On one hand, there was competition among alpha-1,2-
fucosyltransferases, alpha-1,3(4) fucosyltransferases and alpha-2,3-
sialyltransferases [23,40,41], and on the other between alpha-2,3-
sialyltransferases and alpha-2,6-sialyltransferases [6,31,42].
The molecular mechanisms regulating pancreatic tumour
metastasis are still poorly understood. One crucial step is the
attachment of tumour cells to activated endothelial cells, which
involves their adhesion to endothelial selectins that recognize
oligosaccharide determinants expressed on cancer cells surface.
SLe
x has been reported to participate in the first steps of the
extravasation through interaction with E-Selectin by facilitating
the rolling and attachment of tumour cells to the endothelial cells
[27,28,43,44,45]. A direct correlation between ST3Gal III levels,
SLe
x levels and colon cancer cell adhesion to IL-1b activated
human umbilical vein endothelial cells (HUVEC) has been
described [46]. SLe
x expressing colon cancer cells have been also
reported to adhere to hepatic sinusoidal endothelial cells via E-
selectin-SLe
x interaction [47]. Furthermore, several works report-
ed a correlation between SLe
x, and the adhesion to cytokine
stimulated HUVEC in H7721 hepatocarcinoma [48,49,50,51]
and in lung adenocarcinoma cells [52]. In agreement with these
data, our results showed a direct correlation between pancreatic
adenocarcinoma adhesion to in vitro rh-E-selectin and ST3Gal III
levels in pancreatic tumour cells, via SLe
x. Moreover, when
studying the adhesion of pancreatic adenocarcinoma cells to
hepatic sinusoidal endothelial cells, ST3Gal III and SLe
x
overexpressing C31 cells demonstrated an enhanced ability to
adhere to IL-1b stimulated HSE cells compared with controls.
HSE cell pre-treatment with IL1-b and TNF-a cytokines
significantly increased Capan-1 cell adhesion to HSE cells and
returned to basal levels in anti-E-selectin pre-incubated HSE cells.
Those results are consistent with previous work reporting that E-
selectin expression is low or absent in HSE cells under normal
conditions, but can be up-regulated by cytokines [53], by
hepatocytes [54] or as a response to metastatic tumour cells
[55]. Adhesion of ST3Gal III and SLe
x overexpressing C31 cells
to non-stimulated HSE cells was significantly greater when
compared to control cells Capan-1 and CP. This adhesion was
not reverted when pre-incubating HSE cells with anti-E-selectin,
Figure 6. Kaplan-Meier plots of estimated survival after
injection of MP (MDAPanc-28 mock cells) and M34 (MDA-
Panc-28 ST3Gal III transfected cells). Cells (7610
6) were intra-
splenically injected in nude mice on day 1 of the experiment. Mice were
daily examined and sacrificed when they looked sick. The differences
between groups were assessed by the long-rank test (P=0.019; n=7–8/
group).
doi:10.1371/journal.pone.0012524.g006
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SLe
x-mediated, pancreatic cancer cell adhesion to non-stimulated
HSE cells. This interaction could be mediated by other SLe
x
binding Cell Adhesion Molecules such as P-selectin [55,56] or I-
type Lectins. In fact, a previous study reported the binding of
ST3Gal III overexpressing colon cancer cells to non-activated
HUVEC, suggesting this non-E-selectin dependent SLe
x mediated
adhesion could be due to I-Type lectins [46].
To our knowledge, this is the first report on a positive
correlation between cell migration and ST3Gal III and SLe
x
expression levels in pancreatic adenocarcinoma cells. Despite the
absence of studies on pancreatic cancer cells, some investigations
support our findings. When tumour cell surface a2,3-sialic acid
expression on the MDA-MB-231 breast cancer cell line was
depressed (by inhibiting cellular a2,3-sialyltransferase activity with
soyasaponin I), cell migration significantly decreased [57]. ST3Gal
III overexpression on the glioma cell line U-374 increased a2,3-
linked sialic acid expression on cell surface and resulted in a more
in vitro invasive phenotype [58]. In addition, H7721 hepatocarci-
noma cells showed a direct correlation between the amount of
surface SLe
x expression and migration [50,51,59]. Moreover, SLe
x
was crucial for H7721 migration, since migration was inhibited by
anti-SLe
x MAb and after sialic acid residue elimination [60]. Cell
migration is a multistep process that plays a pivotal role in
metastasis. The initial response of migratory cells to a migration-
promoting agent is to polarize and extend protrusions. These
protrusions are stabilized by extracellular matrix adhesion
molecules, such as integrins, and serve as traction sites for
migration as the cell moves forward over them [61]. There is a
rapidly growing body of evidence that demonstrates that
sialylation influences migration capabilities by modulating the
integrin function [58,62,63,64]. Thus, we hypothesize that
ST3Gal III could be influencing cell migration by altering integrin
sialylation. An increase in a2,3-sialic acid on C31 and M34 cell
surface could also alter the sialylation levels of their integrins,
modulating their extracellular matrix adhesion. Nevertheless,
further investigations are required to address this issue.
Several studies have described a correlation between SLe
x levels
and metastasis or poor survival in patients for several types of
cancer, such as colon cancer [25], gastric carcinoma [26], breast
cancer [65] and pancreatic cancer [66]. Along with those clinical
observations, the expression levels of SLe
x on colon cancer cell
surface [25,67,68] and gastric cancer cell surface [69] correlated
with metastatic potential in animal models. Focusing on pancreatic
cancer, the SLe
x antigen has an important in vivo role, since an
inhibitory effect in tumour establishment and metastatic colonies
growth was observed when mice were treated with anti-SLe
x
antibody [70]. SLe
x cell surface levels have also been found to be
important in determining the degree of metastasis formation.
[71,72] have described how excessive expression of SLe
x in
tumour cells leads to rejection by natural killer cells rather than
tumour formation, while moderate amounts of SLe
x lead to
tumour metastasis.
In our hands, a low number of Capan-1 cells with high-medium
levels of SLe
x did not generate metastasis when intrasplenically
injected into athymic nude mice. In contrast, MDAPanc-28 cells
with low levels of SLe
x were able to form metastases in several
organs, when injected at high numbers. However, the different
behaviour of these two cell lines in tumour metastasis generation
could be explained by a combination of multiple factors, including
gene expression pattern, which is not the aim of this work. ST3Gal
III overexpression in MDAPanc-28 pancreatic cancer cells (M34
cells), which leads to medium expression of SLe
x levels, increased
the ability to tumour establishment, metastasis growth and
decreased survival when compared to MDAPanc-28 mock cells
(MP cells). Thus, a correlation between ST3Gal III expression in
MDAPanc-28 pancreatic cancer cells and metastasis in athymic
nude mice could be established. Although this is the first study that
shows a direct implication of ST3Gal III in tumour and metastasis
formation, other studies had pointed in this direction. Thus, the
overexpression of FUT1, which competes for the same substrate as
ST3Gal III and IV, showed a decrease in the metastatic potential
of pancreatic adenocarcinoma [40] and colon cancer [41] cells
after injection into nude mice.
Our studies have started from the generation of stable
transfectants of ST3Gal III in two different pancreatic adenocar-
cinoma cell lines to globally study the role of this enzyme in key
steps of the tumourigenic process. In this way, we have shown that
this enzyme and its main product, SLe
x, confer on pancreatic
carcinoma cells a major E-selectin adhesion, a high migration
capacity and a high metastatic potential. In addition to the role of
ST3Gal III in these key steps of tumourigenic processes, this
enzyme have recently been reported to be involved in producing
cellular resistance to Taxol in ovarian cancer cells [73]; all
together highlighting the importance of ST3Gal III in tumor
processes. Although ST3Gal III plays an important role in the
above processes, other related sialyltransferases may also contrib-
ute to them. A next step would be to understand the regulation of
these enzymes and to design inhibitors that may down-regulate
their biosynthesis and inhibit these processes.
Materials and Methods
Ethics statement
Animal housing, their care, and experimental conditions were
conducted in conformity with institutional guidelines that are in
compliance with the relevant national and international laws and
policies. All procedures working with animals were performed
according to protocols approved by the University Ethics
Commission on Research and Education of the Basque Country
University, which approved this study (reference 09341).
Stable transfection
The construct rat a2,3-sialyltransferase (rat ST3Gal III) [29]
cloned into pcDNA3.1(+) was a kind gift from Dr. Paulson (The
Scripps Research Institute, La Jolla, CA). The nucleotide sequence
and correct orientation were confirmed by DNA sequencing (ABI
prism 310 genetic analyser, Applied Biosystems, CA).The ST3Gal
III encoding expression vector and the empty pcDNA 3.1
encoding expression vector were transfected into human pancre-
atic adenocarcinoma cell lines Capan-1 (ATCC nuHTB-79,
Rockville, MD) and MDAPanc-28 (a generous gift from Dr.
Frazier from M.D. Anderson Cancer Center, Houston) using
Lipofectamine 2000 and Plus Reagent (Invitrogen Life Technol-
ogies, Frederick, MD). Cells in which the plasmid was stably
integrated were selected with 400 mg/mL (Capan-1 cloned cells)
or 800 mg/mL (MDAPanc-28 cloned cells) of GeneticineH G418
(Gibco, Paisley, UK), and resistant clones were further confirmed
by semi-quantitative PCR.
Culture conditions for transfected cells
Cells were grown in Dulbecco’s modified Eagle’s medium_Glu-
taMAX-I containing 10% Fetal Bovine Serum, 100 U/mL
Penicillin G, 100 mg/mL Streptomycin and 0.25 mg/mL Ampho-
tericin B (all of them from Gibco, Paisley, UK) and kept at 37uCi n
humidified atmosphere containing 5% CO2. Stable transfectants
were supplemented with GeneticineH G-418. Cell growth and
morphology were daily assessed under the field microscope. Cells
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trypsinization and seeding and cell viability was assessed by trypan
blue staining (only cultures displaying .90% viability were used
for further work). For the experiments 3.5610
5 Capan-1 model
cells or 5.5610
5 MDAPanc-28 model cells were seeded in 75 cm
2
flasks (Nunc; Roskilde, Denmark) and cultured during 84 h
(exponential growth). Possible contamination with Mycoplasma
was routinely checked using the VenorH GeM Mycoplasma Dection
Kit (Minerva Biolabs GmnH, Berlin, Germany).
Isolation of Total RNA and semi-quantitative RT-PCR for
ST3 Gal III
Exponentially growing cells were trypsinized and counted. Total
RNA was extracted using the RNeasyH RNA isolation kit
(Quiagen, Hilden, Germany) according to the manufacturer’s
protocol, including on-column DNase digestion using the RNAse-
Free DNase Set (Quiagen GmbH, Hilden, Germany). RNA yield
and purity were determinate spectrophotometrically using a
Nanodrop (ND-1000, Thermo Scientific, Wilmington, DE).
Single-stranded cDNA was synthesized from 2.0 mg of total
RNA using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems Inc, Foster City, CA) according to the
manufacturer’s instructions.
ST3Gal III overexpression was examined by semi-quantitative
PCR using the b-actin expression as internal reference. PCR was
performed using 1.3mL of cDNA, 2 mM MgCl2,5 0mM each
dNTP, 18 pmol each forward (F) and reverse (R) oligonucleotides,
and 1 unit mL
–1 Biotools DNA polymerase (Biotools B&M Labs,
Madrid, Spain) in 20mL reactions. ST3Gal III primers were
designed with Primer3 software [74] to specifically amplify the rat
ST3Gal III cloned gene. Primer sequences were 59-CTGC-
ATGGCTGTGATGAAGT-39_(F) and 59-CAACAGATGGCT-
GGCAACTA-39_ (R). PCR product size was 272 bp and thermal
cycling parameters were as follows: 1 cycle at 90uCfor 2 min, 35
cycles at 94uC for 1 min, 58uC for 1 min, 72uC for 1 min and
30 s, 1 cycle at 72uC for 10 min; using a MyCycler
TM
thermocycler (Bio-Rad Labs Hercules, CA). b-actin primers and
thermal cycling conditions were described in Peracaula et al., 2005
and the size of the PCR product obtained was 838 bp. 15 mL
aliquots of amplified cDNAs were run in 1.5% agarose gels,
stained with 0.5mg/ml ethidium bromide, and visualized under
UV-light. The intensity of the amplified cDNA bands of ST3Gal
III was measured using the Quantity-One software package (Bio-Rad
Labs Hercules, CA) and was normalized to the housekeeping gene
(b-actin) for each cell line. Data were expressed as the mean 6 SD
of the intensity values of the PCR assays performed in triplicate.
ST3Gal III expression by Real-time quantitative PCR
RNA extraction and cDNA synthesis were performed as
described above. Primers and probes sequences for the endogen
gene (b-actin) and ST3Gal III were Custom Taqman Gene
Expression Assays
TM from Applied Biosystems-Applera Hispania
SA, Spain. ST3Gal III primers and probe were specifically
designed along highly conserved regions of both rat and human
ST3Gal III transcripts (positions 318 or 330). All PCRs were
performed in optical 96-well plates with an ABI PRISM 7300
Sequence Detector System in a total volume of 20 ml containing
9 ml of cDNA diluted in RNAse free water, 10 ml of TaqManH
Universal Master Mix No AmpEraseH and 1 ml of the corre-
sponding Custom Taqman Gene Expression Assay
TM. The
following standard thermal profile was used for all PCRs: 95uC
for 10 min; 40 cycles of 95uC for 15 s and 60uC for 1 min. All data
were processed and analyzed with 7300 SDS 1.3.1 software
(Applied Biosystems). For each sample dilution, logarithmic
increase in fluorescence signal (DRn) was obtained. DRn threshold
was set at 0.02 to obtain the corresponding Ct (threshold cycle)
values. The relative concentrations of the target and the reference
gene were calculated by interpolation from the corresponding
standard curves. The endogenous housekeeping gene b-actin was
used to normalize the results. To estimate the intra-assay
variability, six technical replicates were performed for each sample
and gene. To estimate the inter-assay variation, PCR assays were
performed in triplicate. Results were expressed as mean 6 SD
values of the relative ST3Gal III transcript abundance normalized
with corresponding b-actin.
GISA (Glycosylation ImmunoSorbent Assay)
GISA was performed as described previously [24]. Briefly,10 ng
of asialofetuin (Roche) were bound for 1 hour at 37uC to 96-well
polystyrene plates in coating buffer (Scil Diagnostics, Germany).
After washing them, plates were blocked with 1% BSA, 0.05% (v/
v) Tween and were incubated for two hours at 37uC with the
different quantities of the cell protein extracts from Capan-1, CP,
C31, MDAPanc-28, MP and M34 (5–25 mg) and 0.77 mg/L of
CMP-5-fluoresceinyl -NeuAc (CMP-5-(N-fluoresceinylthioureido-
acetyl-neuraminic acid) in 45 mM NaCl, 15 mM Tris-HCl,
pH 7.2, 1% Triton X-100 and 0.1% BSA. Plates were washed
and an antibody against FITC (fluorescein isothiocyanate),
peroxidase-conjugated 1:2000 in PBS, 0.05% Tween, 0.25%
BSA was added and allowed to stand for one hour at 37uC. Plates
were washed again and detection was performed with 100 ml/well
of 3,39,5,59-tetramethylbenzidine (TMB) (BM BluePOD substrate
soluble, Roche). The reaction was stopped with 100 ml/well of
0.25M H2SO4 and the absorption was measured at 450 nm
(against a reference wavelength of 630 nm) in an automated
microplate reader (BIO-TEK, USA). Negative controls were wells
without protein extract, or without the CMP-5-fluoresceinyl-
NeuAc. Positive controls were wells with recombinant rat a2,6-N-
Sialyltransferase (Calbiochem, Germany) instead of the cell
protein extracts.
Antibodies and Flow Cytometry analysis
Monoclonal antibodies (MAb) T-218 (anti-Lewis b) and T174
(anti-Lewis a) [75] were used at 1:2 dilution hybridoma
supernatant; 19-OLE (anti -H type 2) and anti-H type1 [76] were
used as ascites diluted at 1/1000. MAb KM93 (anti-SLe
x), MAb
P12 (anti-Le
x), MAb KM231 (anti- SLe
a) and MAb F3 (anti-Le
y)
(all of them from Calbiochem, EMD Chemicals, Inc. San Diego,
CA). Biotinylated Sambucus Nigra (Elderberry Bark) Lectin, which
recognizes most Siaa2,6-terminal structures and biotinylated
Maackia amurensis lectin, which binds to certain terminal Siaa2,3-
terminal structures but not to SLe
x determinants (Vector
Laboratories, Inc. Burlingame, CA) were diluted following
manufacturer’s instructions. Detection of oligosaccharide epitopes
on the surface of exponential growing cells was carried out by
indirect fluorescence as previously described [41]. Briefly, 5610
5
viable cells were incubated with the antibodies or the lectin and
after a wash; cells were then incubated with the secondary
antibody Alexa Fluor 488 goat anti-mouse IgG or Streptavidin
Alexa Fluor 488 (Invitrogen Life Technologies, Frederick, MD).
Fluorescent analysis was performed using a FACSCalibur (BD
Biosciences). For each sample three independent assays were
undertaken.
E-selectin binding assay
Adhesion of pancreatic adenocarcinoma cells to recombinant
human E-selectin (rh-E-selectin) was performed as previously
described [41]. 96-well microplates were coated with rh-E-selectin
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blocked and 5610
4 viable Capan-1, CP or C31 cells or 1610
5
MDAPanc-28, MP or M34 cells, were added and incubated at
room temperature for 1 h. In selected experiments, cells were
previously incubated with specific antibodies for 30 min at 4uC.
After two washes, adherent cells were estimated with a Thiazolyl
Blue (Sigma-Aldrich, St. Louis, MO) based colorimetric method.
All the experiments were performed in quintuplicate, and three
independent assays were undertaken. Results were expressed as
the mean 6 SD values of specific binding to E-selectin (O.D.
570 nm of cells bonded to E-selectin – O.D. 570 nm of cells
bonded to PBS-1% BSA).
Isolation and primary culture of hepatic sinusoidal
endothelium (HSE) cells
Syngenic Balb/c mice (male, 6–8 weeks old) were obtained from
Harlan Iberica (Barcelona, Spain). HSE cells were separated from
these mice, identified, and cultured as previously described [77].
Tumour cell adhesion assay to Primary Cultured Hepatic
Sinusoidal endothelium (HSE) cells
Adhesion assays were performed using a quantitative method
based on a previously described fluorescence measurement system
[78]. Isolated HSE cells were incubated for 16 hours with 10 ng/ml
recombinant Interleukin IL-1b, 10 ng/ml recombinant TNF-a or
10 ng/ml Lipopolysaccharide (LPS) (all from R & D Systems)
before addition of cancer cells. 2 mg/mL anti-murine CD62 E (E-
selectin) MAb (Acris Antibodies GmbH, Herford, Germany) was
added to HSE 30 minutes before tumour cell addition. Anti-murine
IgG antibody was added at a similar concentration and time to
check the specificity of the anti-murine E-selectin antibody.
Exponentially growing Capan-1 clones were trypsinized and
resuspended in 20 mg Calcein AM (Invitrogen Life Technologies,
Frederick, MD) DMEM solution. After washing, cells were
resuspended in HEPES-buffered Dubelco’s modified Eagle medium
without phenol red at a concentration of 2610
6 cells per millilitre.
HSE cells were washed and basal autofluorescence was determined
using a CytoFluor-2350 system (Millipore Co., Bedford, MA).
Labelled Capan-1 clones (0.1 mL per well) were added to 24-well-
plate cultured HSE cells or to collagen pre-coated control wells. To
determine the fluorescence of the added number of cells in each
well, a second determination was performed on the CytoFluor
system. The plates were then incubated at 37uC, and 15 minutes
later, wells were washed three times with fresh medium and read for
a third time for fluorescence. Each experiment was performed in
triplicate wells and three independents assays were undertaken. The
number of adhering cells was quantified in arbitrary fluorescence
units based on the percentage of the initial number of cancer cells
added to the endothelia and results were expressed as the mean 6
SD values of % Specific adhesion to HSE cells [78].
Transwell in vitro migration assays
The effect of ST3Gal III expression on Capan-1 and
MDAPanc-28 cell migration was determined using modified
Boyden chambers as previously described [79]. Cells were
detached and resuspended in serum-free medium. 1610
4
Capan-1 cells or 2.5610
4 MDAPanc-28 cells were seeded onto
Type I-Collagen coated inserts with 8 mm-pores and placed on top
of 2 cm
2 wells (Greiner Bio-One GmbH, Kremsmu ¨nster, Austria)
containing 300 mL DMEM plus 1% FBS (as a chemoattractant).
After incubation at 37uC, 6 hours for Capan-1 cells and 18 hours
for MDAPanc-28, non-migrated cells on the upper surface of the
filter were carefully and thoroughly wiped from the top surface of
the filter and migrated cells were fixed, stained with Haematoxylin
and Eosin (H&E) and counted in 640 high-power light
microscopy. Results were expressed as the average number of
migrated cells per well obtained from three separate experiments
done in triplicate.
In vivo assays in athymic nude mice
Athymic Nude-Fox n1 nu/nu mice (male, 6–8 weeks old)
weighing 21.9–24.8 g were obtained from Charles River (Barce-
lona, Spain). In vivo assay optimal conditions were assessed by
intrasplenic injection into anesthetized mice (50 mg/kg pentobar-
bital i.p) of exponentially growing 1610
6, 1,5610
6,3 610
6 and
5610
6 Capan-1 viable cells and 7610
6 MDAPanc-28 viable cells
suspended in 0.1 ml Hanks’Balanced solution (Gibco, UK).
MDAPanc-28 model analysis was performed by intrasplenic
injection into anesthetised mice (n=8 per group) of exponentially
growing 7610
6 MP and M34 viable cells. Mice were daily
examined for survival and sacrificed when looked sick. Healthy
mice from both experimental groups were also sacrificed to check
for internal signs of malignancy and censored in the survival
analysis. For necropsied animals, macroscopical analysis was
performed and the incidence of tumour lesions in liver, spleen
lung, lymph nodes, and other peritoneal organs were registered.
Statistical Analysis
Data (x) were expressed as means 6 standard deviation (SD).
Statistical analyses were performed using SigmaStat 3.5 for
Windows (Systat Sofware, Inc., San Jose ´, CA) and SPSS statistical
software for Windows (version 15.0; SPSS Inc., Chicago, IL).
Normality of data (x) was tested using the Kolmogorov-Smirnov
test and the homogeneity of variances was checked using the
Levene’s test. Data with normal distribution and homogeneous
variances were analyzed with Student’s t test, one-way or three-
way ANOVA using Tukey’s test for multiple comparisons. For
heterocedastic data, ANOVA on ranks (Kruskal-Wallis test) was
run using Dunn’s method for pairwise multiple comparisons. On
the other hand, time to survival data in experimental metastasis
assay were analyzed by Kaplan-Meier method and compared by
the long-rank test. The criterion for significance was set at P,0.05.
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